Payer Perspectives on Drug Delivery

Alex Guth is a Managing Director and Partner in LEK Consulting’s Boston office and a member of the Life Sciences practice. He supports clients throughout the life sciences industry, including biopharma, manufacturing and academic partners. Alex advises clients across a range of strategic needs, including therapeutic area strategy, portfolio prioritization, due diligence, and opportunity forecasting and valuation. Prior to joining LEK, Alex had over 15 years of experience in biological research. He holds a bachelor’s degree with highest departmental honors in biology and a PhD in virology, both from Harvard University.

Gail Ryan is the Director of Pharmaceutical Transformation at Point32Health.  Point32Health, a health services company serving over 2.2 million lives in the New England area, is the parent company of two legacy organizations, Harvard Pilgrim Health Care and Tufts Health Plan. Dr Ryan earned her BS and her PharmD from the Massachusetts College of Pharmacy and Health Scieånces, and she has almost 20 years of managed care experience with proficiency in clinical pharmacy, medical policy, trend analysis, cost management initiatives, new and emerging technologies, and innovative payment models.

Michael Sherman is a Venture Partner at RA Ventures. Prior to joining RAVen, Dr Sherman was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Prior to Point32Health, Dr Sherman served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). Dr Sherman has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Before pursuing an MBA at Harvard Business School, Dr Sherman received his MD from Yale and practiced as a cardiac anesthesiologist. He also holds a BA in Anthropology and Natural Sciences and an MS in Biomedical Anthropology from the University of Pennsylvania. Dr Sherman is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council.

Dr. Majmundar is a seasoned physician executive with over two decades of experience across the public, private, pharmaceutical and payer sectors, including clinical practice serving in multi-specialty group practice, FQHC,  emergency room and academic settings. She recently served as Chief Medical Officer for a startup commercial health plan and prior to this role served as a medical director for a large managed care organization. She holds dual board certifications in Family Medicine and Health Care Quality and Management. Connect with her on LinkedIn.